Supernus Pharma (SUPN) Tops Q2 EPS by 14c, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Supernus Announces Second Quarter 2018 Financial Results and Record Quarterly Revenue
August 7, 2018 4:16 PM EDTTotal revenue of $99.5 million, a 31% increase over 2017Net product sales of $97.0 million, a 32% increase over 2017Operating earnings of $35.7 million, a 37% increase over 2017Diluted earnings per share (GAAP) of $0.57, a 78% increase over 2017Completed enrollment in the first SPN-812 Phase III trial (P301), with data expected in the fourth quarter of 2018
ROCKVILLE, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Â - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported record financial results for the second quarter of 2018 and... More
